Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures

Robert Cannon, Susan Ellis, David Hayes, Govindarajan Narayanan, Robert C G Martin

Research output: Contribution to journalArticle

186 Citations (Scopus)

Abstract

Introduction Irreversible electroporation (IRE) has shown promise for ablation of lesions in proximity to vital structures in the preclinical setting. This study aims to evaluate the safety and efficacy of IRE for hepatic tumors in the clinical setting. Methods An IRB approved prospective registry of patients undergoing IRE for hepatic tumors over a 2-year period. Factors analyzed included patient and tumor characteristics, treatment related complications, and local recurrence free survival (LRFS) for ablated lesions. LRFS was calculated according to Kaplan-Meier, with secondary analyses stratified by procedural approach (laparotomy, laparoscopy, and percutaneous) and tumor histology. Results There were 44 patients undergoing 48 total IRE procedures, 20 colorectal mets, 14 hepatocellular, and 10 other metastatsis. Initial success was achieved in 46 (100%) treatments. Five patients had 9 adverse events, with all complications resolving within 30 days. LRFS at 3, 6, and 12 months was 97.4%, 94.6%, and 59.5%. There was a trend toward higher recurrence rates for tumors over 4 cm (HR 3.236, 95% CI: 0.585-17.891; P = 0.178). Conclusions IRE appears to be a safe treatment for hepatic tumors in proximity to vital structures. Further prospective evaluation is needed to determine the optimal effectiveness of IRE in relation to size and technique for IRE of the liver.

Original languageEnglish
Pages (from-to)544-549
Number of pages6
JournalJournal of Surgical Oncology
Volume107
Issue number5
DOIs
StatePublished - Apr 1 2013

Fingerprint

Electroporation
Safety
Liver
Neoplasms
Recurrence
Survival
Research Ethics Committees
Laparoscopy
Laparotomy
Registries
Histology
Therapeutics

Keywords

  • hepatic metastasis
  • hepatocellular carcinoma
  • irreversible electroporation

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. / Cannon, Robert; Ellis, Susan; Hayes, David; Narayanan, Govindarajan; Martin, Robert C G.

In: Journal of Surgical Oncology, Vol. 107, No. 5, 01.04.2013, p. 544-549.

Research output: Contribution to journalArticle

Cannon, Robert ; Ellis, Susan ; Hayes, David ; Narayanan, Govindarajan ; Martin, Robert C G. / Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. In: Journal of Surgical Oncology. 2013 ; Vol. 107, No. 5. pp. 544-549.
@article{e8fe1c3277574d42befa9c86e7bdcad8,
title = "Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures",
abstract = "Introduction Irreversible electroporation (IRE) has shown promise for ablation of lesions in proximity to vital structures in the preclinical setting. This study aims to evaluate the safety and efficacy of IRE for hepatic tumors in the clinical setting. Methods An IRB approved prospective registry of patients undergoing IRE for hepatic tumors over a 2-year period. Factors analyzed included patient and tumor characteristics, treatment related complications, and local recurrence free survival (LRFS) for ablated lesions. LRFS was calculated according to Kaplan-Meier, with secondary analyses stratified by procedural approach (laparotomy, laparoscopy, and percutaneous) and tumor histology. Results There were 44 patients undergoing 48 total IRE procedures, 20 colorectal mets, 14 hepatocellular, and 10 other metastatsis. Initial success was achieved in 46 (100{\%}) treatments. Five patients had 9 adverse events, with all complications resolving within 30 days. LRFS at 3, 6, and 12 months was 97.4{\%}, 94.6{\%}, and 59.5{\%}. There was a trend toward higher recurrence rates for tumors over 4 cm (HR 3.236, 95{\%} CI: 0.585-17.891; P = 0.178). Conclusions IRE appears to be a safe treatment for hepatic tumors in proximity to vital structures. Further prospective evaluation is needed to determine the optimal effectiveness of IRE in relation to size and technique for IRE of the liver.",
keywords = "hepatic metastasis, hepatocellular carcinoma, irreversible electroporation",
author = "Robert Cannon and Susan Ellis and David Hayes and Govindarajan Narayanan and Martin, {Robert C G}",
year = "2013",
month = "4",
day = "1",
doi = "10.1002/jso.23280",
language = "English",
volume = "107",
pages = "544--549",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures

AU - Cannon, Robert

AU - Ellis, Susan

AU - Hayes, David

AU - Narayanan, Govindarajan

AU - Martin, Robert C G

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Introduction Irreversible electroporation (IRE) has shown promise for ablation of lesions in proximity to vital structures in the preclinical setting. This study aims to evaluate the safety and efficacy of IRE for hepatic tumors in the clinical setting. Methods An IRB approved prospective registry of patients undergoing IRE for hepatic tumors over a 2-year period. Factors analyzed included patient and tumor characteristics, treatment related complications, and local recurrence free survival (LRFS) for ablated lesions. LRFS was calculated according to Kaplan-Meier, with secondary analyses stratified by procedural approach (laparotomy, laparoscopy, and percutaneous) and tumor histology. Results There were 44 patients undergoing 48 total IRE procedures, 20 colorectal mets, 14 hepatocellular, and 10 other metastatsis. Initial success was achieved in 46 (100%) treatments. Five patients had 9 adverse events, with all complications resolving within 30 days. LRFS at 3, 6, and 12 months was 97.4%, 94.6%, and 59.5%. There was a trend toward higher recurrence rates for tumors over 4 cm (HR 3.236, 95% CI: 0.585-17.891; P = 0.178). Conclusions IRE appears to be a safe treatment for hepatic tumors in proximity to vital structures. Further prospective evaluation is needed to determine the optimal effectiveness of IRE in relation to size and technique for IRE of the liver.

AB - Introduction Irreversible electroporation (IRE) has shown promise for ablation of lesions in proximity to vital structures in the preclinical setting. This study aims to evaluate the safety and efficacy of IRE for hepatic tumors in the clinical setting. Methods An IRB approved prospective registry of patients undergoing IRE for hepatic tumors over a 2-year period. Factors analyzed included patient and tumor characteristics, treatment related complications, and local recurrence free survival (LRFS) for ablated lesions. LRFS was calculated according to Kaplan-Meier, with secondary analyses stratified by procedural approach (laparotomy, laparoscopy, and percutaneous) and tumor histology. Results There were 44 patients undergoing 48 total IRE procedures, 20 colorectal mets, 14 hepatocellular, and 10 other metastatsis. Initial success was achieved in 46 (100%) treatments. Five patients had 9 adverse events, with all complications resolving within 30 days. LRFS at 3, 6, and 12 months was 97.4%, 94.6%, and 59.5%. There was a trend toward higher recurrence rates for tumors over 4 cm (HR 3.236, 95% CI: 0.585-17.891; P = 0.178). Conclusions IRE appears to be a safe treatment for hepatic tumors in proximity to vital structures. Further prospective evaluation is needed to determine the optimal effectiveness of IRE in relation to size and technique for IRE of the liver.

KW - hepatic metastasis

KW - hepatocellular carcinoma

KW - irreversible electroporation

UR - http://www.scopus.com/inward/record.url?scp=84875235955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875235955&partnerID=8YFLogxK

U2 - 10.1002/jso.23280

DO - 10.1002/jso.23280

M3 - Article

VL - 107

SP - 544

EP - 549

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 5

ER -